Highbridge Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Highbridge Capital Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,413,487	Closed	-$3.31M	–	471
2022 Q4	$3.31M	Hold	2,413,487	–	–	0.09%	203
2022 Q3	$2.51M	Buy	+2,413,487	New	+$2.67M	0.04%	312
2020 Q4	–	Sell	-2,414,487	Closed	-$9.42M	–	127
2020 Q3	$9.42M	Hold	2,414,487	–	–	0.51%	52
2020 Q2	$9.15M	Sell	2,414,487 -2,414,487	-50%	-$8.25M	0.78%	33
2020 Q1	$11.3M	Buy	+4,828,974	New	+$16M	1.21%	32
2018 Q1	–	Sell	-47,255	Closed	-$313K	–	1594
2017 Q4	$313K	Sell	47,255 -410,812	-90%	-$2.77M	0.01%	1212
2017 Q3	$2.66M	Buy	+458,067	New	+$2.93M	0.04%	388
2017 Q1	–	Sell	-477,980	Closed	-$4.3M	–	1644
2016 Q4	$2.13M	Buy	+477,980	New	+$2.14M	0.04%	376
2014 Q1	–	Sell	-2,296	Closed	-$89K	–	1206
2013 Q4	$89K	Buy	+2,296	New	+$96.7K	﹤0.01%	1011

Other funds holding PLX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Highbridge Capital Management's PLX Position: Q1 2023 in Review

Highbridge Capital Management sold out of Protalix BioTherapeutics (PLX) in Q1 2023, closing a stake of 2,413,487 shares — an estimated $3.31M sold.

Highbridge Capital Management first reported a position in PLX in Q4 2013 and held it in 9 quarters. The position peaked at $11.3M in Q1 2020. 34 funds tracked by Wall St. Rank hold PLX as of Q1 2023.

Highbridge Capital Management reported no remaining Protalix BioTherapeutics position as of Q1 2023 after selling out during the quarter.
Highbridge Capital Management sold 2,413,487 Protalix BioTherapeutics shares in Q1 2023, an estimated $3.31M.
Highbridge Capital Management first reported a position in Protalix BioTherapeutics in Q4 2013 and held it in 9 quarters.
Highbridge Capital Management's Protalix BioTherapeutics position peaked at $11.3M in Q1 2020.
34 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2023.

Based on Highbridge Capital Management's 13F filing for Q1 2023, filed 11 May 2023.